Advanced search
Publication Cover
Hematology Volume 15, 2010 - Issue 5
Submit an article Journal homepage
171
Views
18
CrossRef citations to date
0
Altmetric
Hematological Malignancy: Current Clinical Practice: Review

Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia – a report of five cases

Hanne FredlySection for HematologyInstitute of Medicine and Dentistry, University of Bergen, Norway; Division for Hematology, Department of Medicine, Haukeland University Hospital, Bergen, Norway
,
Camilla Stapnes BjørnsenSection for HematologyInstitute of Medicine and Dentistry, University of Bergen, Norway; Division for Hematology, Department of Medicine, Haukeland University Hospital, Bergen, Norway
,
Bjørn Tore GjertsenSection for HematologyInstitute of Medicine and Dentistry, University of Bergen, Norway; Division for Hematology, Department of Medicine, Haukeland University Hospital, Bergen, Norway
&
Øystein BruserudSection for HematologyInstitute of Medicine and Dentistry, University of Bergen, Norway; Division for Hematology, Department of Medicine, Haukeland University Hospital, Bergen, Norway
Pages 338-343 | Published online: 18 Jul 2013

References

  • Burnett AK, Milligan D, Prentice AG et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007; 109: 1114–1124.
  • Bellos F, Mahlknecht U. Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients. Onkologie 2008; 31: 629–633.
  • Bruserud O, Stapnes C, Ersvaer E, Gjertsen BT, Ryningen A. Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell. Curr Pharm Biotechnol 2007; 8: 388–400.
  • Bruserud O, Stapnes C, Tronstad KJ, Ryningen A, Aanensen N, Gjertsen BT. Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML. Expert Opin Ther Targets 2006; 10: 51–68.
  • Bug G, Ritter M, Wassmann B et al. Clinical trial of valproic acidand all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 2005; 104: 2717–2725.
  • Kuendgen A, Knipp S, Fox F et al. Results of a phase 2 study ofvalproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann Hematol 2005; 84(Suppl 1): 61–66.
  • Kuendgen A, Schmid M, Schlenk R et al. The histone deacetylase(HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006; 106: 112–119.
  • Pilatrino C, Cilloni D, Messa E et al. Increase in platelet count inolder, poor-risk patients with acute myeloid leukemia or myelo-dysplastic syndrome treated with valproic acid and all-trans retinoic acid. Cancer 2005; 104: 101–109.
  • Raffoux E, Chaibi P, Dombret H, Degos L. Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia. Haematologica 2005; 90: 986–988.
  • Ryningen A, Stapnes C, Lassalle P, Corbascio M, Gjertsen BT, Bruserud O. A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid. Leuk Res 2009; 33: 779–787.
  • Ryningen A, Stapnes C, Paulsen K, Lassalle P, Gjertsen BT, Bruserud O. In vivo biological effects of ATRA in the treatment of AML. Expert Opin Investig Drugs 2008; 17: 1623–1633.
  • Hauswald S, Duque-Afonso J, Wagner MM et al. Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. Clin Cancer Res 2009; 15: 3705–3715.
  • Fredly H, Ersvxr E, Stapnes C, Gjertsen BT, Bruserud O. The combination of conventional chemotherapy with new targeted therapy in hematologic malignancies: the safety and efficiency of low-dose cytarabine supports its combination with new therapeutic agents in early clinical trials. Curr Cancer Ther Rev 2009; 5: 243–255.
  • Karran P. Thiopurines, DNA damage, DNA repair and therapy-related cancer. Br Med Bull 2006; 79–80: 153–170.
  • Gwilt PR, Tracewell WG. Pharmacokinetics and pharmacody-namics of hydroxyurea. Clin Pharmacokinet 1998; 34: 347–358.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.